Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia

Psychiatry Research

Volumn 186, Issue 1, 2011, Pages 23-27

  Sumiyoshi, Tomiki ^a,b   Higuchi, Yuko ^a   Matsui, Mie ^a,b   Itoh, Hiroko ^a   Uehara, Takashi ^a   Itoh, Toru ^a   Arai, Hirofumi ^a   Takamiya, Chieko ^a   Suzuki, Michio ^a,b   Kurachi, Masayoshi ^a,b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Antipsychotic drugs; Cognition; Essential polyunsaturated fatty acids; Phospholipids; Schizophrenia; Social function

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; LINOLENIC ACID; OLANZAPINE; PALMITIC ACID; PEROSPIRONE; STEARIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFICACY; ERYTHROCYTE LEVEL; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; HUMAN CELL; MALE; MEMBRANE COMPONENT; OUTCOME ASSESSMENT; PHOSPHOLIPID MEMBRANE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; SCHIZOPHRENIA; TASK PERFORMANCE; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; CELL MEMBRANE; CHRONIC DISEASE; ERYTHROCYTES; FATTY ACIDS; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; SCHIZOPHRENIA; STATISTICS AS TOPIC;

EID: 79951852168     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.07.049     Document Type: Article

References (44)

1. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) 1983, University of Iowa, Iowa City.
2. Andreasen N.C. Scale for the Assessment of Positive Symptoms (SAPS) 1983, University of Iowa, Iowa City.
3. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophrenia Research 2003, 62:195-204.
4. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., Bennet C., Ranjekar P.K., Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry 2003, 53:56-64.
5. Assies J., Lieverse R., Vreken P., Wanders R.J., Dingemans P.M., Linszen D.H. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biological Psychiatry 2001, 49:510-522.
6. Bennett C.N., Horrobin D.F. Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update. Prostaglandins Leukotriene and Essential Fatty Acids 2000, 63:47-59.
7. Chan A.S., Chiu H., Lam L., Pang A., Chow L.Y. A breakdown of event schemas in patients with schizophrenia: an examination of their script for dining at restaurants. Psychiatry Research 1999, 87:169-181.
8. Condray R., Yao J.K., Steinhauer S.R., van Kammen D.P., Reddy R.D., Morrow L.A. Semantic memory in schizophrenia: association with cell membrane essential fatty acids. Schizophrenia Research 2008, 106:13-28.
9. Connor W.E., Neuringer M., Lin D.S. Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. Jounral of Lipid Research 1990, 31:237-247.
10. Delion S., Chalon S., Herault J., Guilloteau D., Besnard J.C., Durand G. Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotonergic neurotransmission in rats. Journal of Nutrition 1994, 124:2466-2476.
11. Doris A.B., Wahle K., MacDonald A., Morris S., Coffey I., Muir W., Blackwood D. Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia. Schizophrenia Research 1998, 31:185-196.
12. Elizabeth Sublette M., Milak M.S., Hibbeln J.R., Freed P.J., Oquendo M.A., Malone K.M., Parsey R.V., John Mann J. Plasma polyunsaturated fatty acids and regional cerebral glucose metabolism in major depression. Prostaglandins Leukotriene Essential Fatty Acids 2009, 80:57-64.
13. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukotrienes and Essent Fatty Acids 2003, 69:393-399.
14. Fenton W.S., Hibbeln J., Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry 2000, 47:8-21.
15. Glen A.I., Glen E.M., Horrobin D.F., Vaddadi K.S., Spellman M., Morse-Fisher N., Ellis K. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophrenia Research 1994, 12:53-61.
16. Hagan J.J., Jones D.N. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophrenia Bulletin 2005, 31:830-853.
17. Hibbeln J.R. Fish consumption and major depression. Lancet 1998, 351:1213.
18. Higuchi Y., Sumiyoshi T., Kawasaki Y., Matsui M., Arai H., Kurachi M. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300. Schizophrenia Research 2008, 101:320-330.
19. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Research 1998, 30:193-208.
20. Kaddurah-Daouk R., McEvoy J., Baillie R.A., Lee D., Yao J.K., Doraiswamy P.M., Krishnan K.R. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Molecular Psychiatry 2007, 12:934-945.
21. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia Research 2002, 58:1-10.
22. Maes M., Christophe A., Delanghe J., Altamura C., Neels H., Meltzer H.Y. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Research 1999, 85:275-291.
23. Maes M., Smith R., Christophe A., Cosyns P., Desnyder R., Meltzer H. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. Journal of Affective Disorders 1996, 38:35-46.
24. Matsui M., Sumiyoshi T., Yuuki H., Kato K., Kurachi M. Impairment of event schema in patients with schizophrenia: examination of script for shopping at supermarket. Psychiatry Research 2006, 143:179-187.
25. McNamara R.K., Able J.A., Jandacek R., Rider T., Tso P. Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis. Schizophrenia Research 2009, 107:150-157.
26. McNamara R.K., Jandacek R., Rider T., Tso P., Hahn C.G., Richtand N.M., Stanford K.E. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophrenia Research 2007, 91:37-50.
27. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry 2003, 27:1159-1172.
28. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999, 25:233-255.
29. Ohara K. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry 2007, 31:469-474.
30. Peet M., Horrobin D.F. A dose-ranging exploratory study of the effects of ethyl- eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatry Research 2002, 36:7-18.
31. Peet M., Laugharne J., Rangarajan N., Horrobin D., Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. Jounral of Psychiatry Research 1995, 29:227-232.
32. Polymeropoulos M.H., Licamele L., Volpi S., Mack K., Mitkus S.N., Carstea E.D., Getoor L., Thompson A., Lavedan C. Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. Schizophrenia Research 2009, 108:134-142.
33. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., Wagh U.V., Debsikdar V.B. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research 2003, 121:109-122.
34. Reddy R.D., Keshavan M.S., Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophrenia Bulletin 2004, 30:901-911.
35. Richardson A.J., Allen S.J., Hajnal J.V., Cox I.J., Easton T., Puri B.K. Associations between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes. Progress in Neuropsychopharmacology & Biological Psychiatry 2001, 25:1513-1521.
36. Sumiyoshi T., Hasegawa M., Jayathilake K., Meltzer H.Y. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiatry Research 1997, 69:113-121.
37. Sumiyoshi T., Higuchi Y., Itoh T., Matsui M., Arai H., Suzuki M., Kurachi M., Kawasaki Y. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLORETA. Psychiatry Research Neuroimaging 2009, 172:180-183.
38. Sumiyoshi T., Matsui M., Itoh H., Higuchi Y., Arai H., Takamiya C., Kurachi M. Essential polyunsaturated fatty acids and social cognition in schizophrenia. Psychiatry Research 2008, 157:87-93.
39. Sumiyoshi T., Roy A., Kim C.H., Jayathilake K., Lee M.A., Sumiyoshi C., Meltzer H.Y. Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia. Psychopharmacology (Berl) 2004, 177:79-83.
40. Vaddadi K.S., Courtney P., Gilleard C.J., Manku M.S., Horrobin D.F. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Research 1989, 27:313-323.
41. Yao J., Stanley J.A., Reddy R.D., Keshavan M.S., Pettegrew J.W. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biological Psychiatry 2002, 52:823-830.
42. Yao J.K., van Kammen D.P. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Schizophrenia Research 1994, 11:209-216.
43. Yao J.K., van Kammen D.P., Gurklis J. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophrenia Research 1994, 13:227-232.
44. Yao J.K., van Kammen D.P., Welker J.A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophrenia Research 1994, 13:217-226.